-
Anti-corruption & international risk developments
2:47
Alex Rene, co-chair of Ropes & Gray’s anti-corruption / international risk practice and managing partner of the firm’s Washington, D.C. office, discusses recent FCPA enforcement activity as well as international risks facing companies.
-
Cybersecurity in the investment management industry
3:48
Paulita Pike, Ropes & Gray investment management partner, addresses privacy and cybersecurity challenges facing the investment management industry.
-
Private equity investments
3:29
Neill Jakobe, Ropes & Gray private equity partner and managing partner of the firm’s Chicago office, discusses some of the key trends impacting private equity investments.
-
FTC's merger remedies study
3:14
Jonathan Klarfeld, Ropes & Gray antitrust partner, discusses key takeaways and likely impacts of the Federal Trade Commission's recent divestiture study.
-
Changing values of IP and data in deals
4:50
Ed Black, co-head of Ropes & Gray’s IP transactions and technology, media & telecommunications practice groups, discusses changing values of IP and data in M&A transactions.
-
UK corporate offence of failure to prevent tax evasion
4:24
Andrew Howard, Ropes & Gray tax partner, discusses the UK’s new corporate criminal offence of failure to prevent tax evasion, which goes into effect in September 2017.
-
EU excessive pricing laws
4:14
Ruchit Patel, Ropes & Gray antitrust partner, examines excessive pricing laws in the EU and the increase of cases involving generic pharmaceuticals.
-
Value-based health care: private equity investors
5:12
Deborah Gersh, Ropes & Gray health care partner, discusses considerations for private equity companies investing in the value-based health care space.
-
Value-based health care: fraud & abuse laws
4:26
Michael Lampert, Ropes & Gray health care partner, discusses fraud and abuse law application to value-based health care arrangements.
-
Value-based health care: issues for pharmaceutical companies
4:25
Michael Lampert, Ropes & Gray health care partner, discusses issues facing pharmaceutical companies with the move towards value-based health care models.
-
FCPA Pilot Program
3:21
Ryan Rohlfsen, Ropes & Gray government enforcement partner, analyzes the first year of the U.S. Department of Justice’s FCPA Pilot Program.
- Next Page
